EPO and anemia (phenotype): Recombinant EPO and its derivatives have been widely used for decades as erythropoiesis‐stimulating agents (ESAs) to treat anemia, particularly in patients with chronic kidney disease (CKD) (Bunn, 2007; Chida et al., 1999; Chung et al., 2023).